Celularity (CELU) Total Non-Current Liabilities (2019 - 2025)
Celularity (CELU) posted quarterly Total Non-Current Liabilities of $145.3 million for Q4 2025, up 17.59% year-over-year from $123.6 million in Q4 2024, and up 8.38% quarter-over-quarter from $134.1 million in Q3 2025.
Celularity (CELU) Total Non-Current Liabilities (2019 - 2025) Analysis & Trends
Celularity (CELU) has reported Total Non-Current Liabilities for 7 consecutive years, with $145.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Non-Current Liabilities rose 17.59% year-over-year to $145.3 million; the TTM figure through Dec 2025 stood at $145.3 million (up 17.59% YoY), while the FY2025 annual figure was $145.3 million, up 17.59% from the prior year.
- Total Non-Current Liabilities rose to $145.3 million in Q4 2025 per CELU's latest filing, from $134.1 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $342.4 million in Q1 2022 and bottomed at $16.0 million in Q1 2021.
- Historically, Total Non-Current Liabilities has averaged $163.6 million across 5 years, with a median of $130.4 million in 2023.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities soared 2043.66% — and 2023, when it sank 56.28%.
- Celularity's Total Non-Current Liabilities stood at $314.4 million in 2021, then plunged by 35.8% to $201.8 million in 2022, then tumbled by 49.15% to $102.6 million in 2023, then advanced by 20.39% to $123.6 million in 2024, then increased by 17.59% to $145.3 million in 2025.
- Business Quant data shows CELU's Total Non-Current Liabilities at $145.3 million in Q4 2025, $134.1 million in Q3 2025, and $137.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Celularity | 20.99 Mn | 14.82 Mn | -3.27 Mn | 143.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 145.30 Mn |
| Sep 30, 2025 | 134.06 Mn |
| Jun 30, 2025 | 137.00 Mn |
| Mar 31, 2025 | 126.32 Mn |
| Dec 31, 2024 | 123.57 Mn |
| Sep 30, 2024 | 107.16 Mn |
| Jun 30, 2024 | 99.60 Mn |
| Mar 31, 2024 | 97.48 Mn |
| Dec 31, 2023 | 102.64 Mn |
| Sep 30, 2023 | 126.65 Mn |
| Jun 30, 2023 | 121.64 Mn |
| Mar 31, 2023 | 206.47 Mn |
| Dec 31, 2022 | 201.84 Mn |
| Sep 30, 2022 | 258.79 Mn |
| Jun 30, 2022 | 278.25 Mn |
| Mar 31, 2022 | 342.40 Mn |
| Dec 31, 2021 | 314.38 Mn |
| Sep 30, 2021 | 314.88 Mn |
| Jun 30, 2021 | 18.10 Mn |
| Mar 31, 2021 | 15.97 Mn |